Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study.

ABSTRACT:

Introduction

Immune checkpoint inhibitor (ICI)-based immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has radically changed the management of many types of solid tumors including non-small cell lung cancer (NSCLC). Many clinical trials have demonstrated that ICIs improve the survival and the quality of life of patients with advanced non oncogene NSCLC as compared to standard therapies. However, not all patients achieve a clinical benefit from this immunotherapeutic approach. As a result, real-word validation of the efficacy and safety of ICIs can be useful for defining potential predictive biomarkers as well as for overcoming limitations linked to clinical trial restrictions.

Methods

We retrospectively retrieved the clinical data of patients wit

SUBMITTER: Liguori L 

PROVIDER: S-EPMC11631946 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature